Imaging of dopamine transporters with iodine-123-FP-CIT SPECT in healthy controls and patients with Parkinson's disease

Journal of Nuclear Medicine

Volumn 39, Issue 11, 1998, Pages 1879-1884

  Booij, Jan ^a   Habraken, Jan B A ^b   Bergmans, Paul ^b   Tissingh, Gerrit ^b   Winogrodzka, Ania ^b   Wolters, Erik Ch ^b   Janssen, Anton G M ^b   Stoof, Johannes C ^b   Van Royen, Eric A ^b  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

Cocaine analogs; Dopamine transporter imaging; Iodine 123 FP CIT; Reproducibility; SPECT

Indexed keywords

DOPAMINE TRANSPORTER; N OMEGA FLUOROPROPYL 2BETA CARBOXYMETHOXY 3BETA (4 IODOPHENYL)NORTROPANE I 123; RADIOISOTOPE; UNCLASSIFIED DRUG;

ADULT; AGED; ALGORITHM; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; FEMALE; HUMAN; IMAGE ANALYSIS; MALE; MATHEMATICAL COMPUTING; PARKINSON DISEASE; PRIORITY JOURNAL; RELIABILITY; REPRODUCIBILITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STRIATE CORTEX; TECHNIQUE;

AGED; ALGORITHMS; BRAIN; CARRIER PROTEINS; CASE-CONTROL STUDIES; CORPUS STRIATUM; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; NERVE TISSUE PROTEINS; PARKINSON DISEASE; REPRODUCIBILITY OF RESULTS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TROPANES;

EID: 0031772781     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Leenders KL, Salmon EP, Tyrrell P, et al. The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease. Arch Neurol 1990;47:1290-1298.
2. Innis RB, Seibyl JB, Scanley BE, et al. Single photon computed imaging demonstrates loss of striatal dopamine transporters in Parkinson's disease. Proc Natl Acad Sci USA 1993;90:11965-11969.
3. 123I]β-CIT. Binding kinetics in the human brain. J Neural Transum[GenSect] 1993;94:137-146.
4. 123I]β-CIT binding to dopamine transporters in healthy human subjects. J Cereb Blood Flow Metab 1994;14:982-994.
5. 11C-WIN 35,428 reveals marked declines in mild Parkinson's disease. Ann Neurol 1993;34:423-431.
6. Neumeyer JL, Wang S, Gao Y, et al. N-ω-fluoroalkyl analogs of (1R)-2β-carbomethoxy-3-β-(4-iodophenyl)-tropane (β-CIT): radiotracers for positron emission tomography and single photon emission computed tomography imaging of dopamine transporters. J Med Chem 1994;37:1558-1561.
7. 123I]|N-ω-fluoroalkyl-2β-carboxy-3β-(4-iodophenyl)nortropane esters in baboons. Nucl Med Biol 1995;22:211-219.
8. Kuikka JT, Bergström KA, Ahonen A, et al. Comparison of iodine-123 labelled 2β-carbomethoxy-3β-(4-iodophenyl)tropane and 2β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl)nortropane for imaging of the dopamine transporter in the living human brain. Eur J Nucl Med 1995;22:356-360.
9. 11C]β-CFT in early Parkinson's disease. Synapse 1995;21:97-103.
10. 18F]N-3-fluoropropyl-2-β-carbomethoxy-3-β-(4-iodophenyl)nortropane and the first human study with positron emission tomography. Nucl Med Biol 1996;23:999-1004.
11. 11C]RTI-32 PET studies of the dopamine transporter in early dopa-naive Parkinson's disease: implications for the symptomatic threshold. Neurology 1997;48:1578-1583.
12. Abi-Dargham A, Gandelman MS, DeErausquin GA, et al. SPECT imaging of dopamine transporters in human brain with iodine-123-fluoroalkyl analogs of β-CIT. J Nucl Med 1996;37:1129-1133.
13. Neumeyer JL, Tamagnan G, Wang S, et al. N-substituted analogs of 2β-carbomethoxy-3β-(4′-iodophenyl)tropane (β-CIT) with selective affinity to dopamine or serotonin transporters in rat forebrain. J Med Chem 1996;39:543-548.
14. 123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease. J Neurol Neurosurg Psychiatry 1997;62:133-140.
15. 123I]FP-CIT binds to the dopamine transporter as assessed by biodistribution studies in rats and SPECT studies in MPTP-lesioned monkeys. Synapse 1997;27:183-190.
16. 11C]β-CIT-FP, a potential radioligand for the dopamine transporter: preparation, autoradiography, metabolite studies, and positron emission tomography examinations, Nucl Med Biol 1995;22:905-913.
17. Ishikawa T, Dhawan V, Kazumata K, et al. Comparative nigrostriatal dopaminergic imaging with iodine-123-βCIT-FP/SPECT and fluorine-18-FDOPA/PET. J Nucl Med 1996;37:1760-1765.
18. 123I]FP-CIT SPECT in the demonstration of the dopaminergic deficit in Parkinson's disease. Eur J Nucl Med 1997;24:68-71.
19. 123I]β-CIT-FP. Parkinsonism Relat Dis 1997;3:77-81.
20. 123I]β-CIT: pharmacological characterization of brain uptake in non-human primates. Synapse 1993;13:295-309.
21. Gibb WRG, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988;51:745-752.
22. Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology 1967;17:427-442.
23. Matsui T and Hirano A. An atlas of the human brain for computerized tomography. Stutgartt: Gustav Fisher Verlag; 1978.
24. Press WH, Flannery BP, Teukolsky SA, Vetterling WT. Minimization or maximization of functions. In: WH, Flannery BP, Teukolsky SA, Vetterling WT, eds. Numerical recipes. The art of scientific computing. New York: Cambridge University Press: 1986:274-335.
25. Vingerhoets FJG, Snow BJ, Schulzer M, et al. Reproducibility of fluorine-18-6-fluorodopa positron emission tomography in normal human subjects. J Nucl Med 1994;35:18-24.
26. Vingerhoets FJG, Schulzer M, Ruth TJ, Holden JE, Snow BJ. Reproducibility and discriminating ability of fluorine-18-6-fluorodopa PET in Parkinson's disease. J Nucl Med 1996;37:421-426.
27. Volkow ND, Fowler JS, Wang GJ, et al. Reproducibility of repeated measures of carbon-11-raclopride binding in the human brain. J Nucl Med 1993;34:609-613.
28. 2 receptor occupancy. A PET study in haloperidol-treated patients. Psych Res Neuroimaging 1996;67:163-171.
29. Vander Borght T, Kilbourn M, Desmond T, Kuhl D, Frey K. The vesicular monoamine transporter is not regulated by dopaminergic drug treatments. Eur J Pharmacol 1995;294:577-583.
30. 99mTc]TRODAT-1 to the central dopamine transporters in rats. Eur J Nucl Med 1998;25:31-39.
31. Morisette M, Di Paolo T. Sex and estrous cycle variations of rat striatal dopamine uptake sites. Neuroendocrinology 1993;58:16-22.
32. Morisette M, Biron D, Di Paolo T. Effect of estradiol and progesterone on rat striatal dopamine uptake sites. Brain Res Bull 1990;25:49-422.
33. Morisette M, Di Paolo T. Effects of chronic estradiol and progesterone treatments of ovariectomized rats on brain dopamine uptake sites. J Neurochem 1993;60:1876-1883.
34. Ichise M, Ballinger JR, Vines D, Tsai S, Kung HF. Simplified quantification and reproducibility studies of dopamine D2-receptor binding with iodine-123-IBF SPECT in healthy subjects. J Nucl Med 1997;38:31-37.
35. Seibyl JP, Laruelle M, van Dyck CH, et al. Reproducibility of iodine-123-β-CIT SPECT brain measurement of dopamine transporters. J Nucl Med 1996;37:222-228.
36. Tiihonen J, Kuikka J, Bergström K, Lepola U, Koponen H, Leinonen E. Dopamine reuptake sites densities in patients with social phobia. Am J Psychiatry 1997;154:239-242.
37. Habraken JBA, Booij J, van Royen EA, Slomka PJ. Quantification of the functional dopaminergic system using an automatic algorithm [Abstract]. J Nucl Med 1997;38:60.